Search results
Results from the WOW.Com Content Network
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. [6] It was considered the largest corporate merger in history during that time. [6] The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, “novae artes” (new skills). [6]
He spent eight years working in Novartis Vaccines, and was the Global Head of Development, Novartis Vaccines in the US between 2012 and 2014 before moving to Sandoz as Global Head of Biopharmaceuticals and Oncology Injectables. [6] [17] From 2014 to 2016, he was the Global Head of Development for Novartis Pharmaceuticals.
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. [4] Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz.
Swiss drugmaker Novartis <NOVN.S> has named company veteran Victor Bulto as head of its U.S. pharmaceuticals business, effective on Sept. 1. The statement said Chouraqui had "consistently ...
Novartis boss Vas Narasimhan raised full-year targets on Thursday and announced that $700 million has been set aside in the hope of settling a decade-old lawsuit alleging that the Swiss drugmaker ...
Novartis is poised to prevail in the auction for Cytokinetics, ahead of other bidders that include AstraZeneca and Johnson & Johnson, according to the source. A deal could be announced as early as ...
Chiron Corporation (/ ˈ k aɪ r ɒ n / KY-ron) [1] was an American multinational biotechnology firm founded in 1981, based in Emeryville, California, that was acquired by Novartis on April 20, 2006.
Novartis Gene Therapies, until 2020 known as AveXis, is a biotechnology company that develops treatments for rare neurological genetic disorders. It was founded in Dallas , Texas , United States in 2012 by John Carbona after reorganizing a company called BioLife Cell Bank founded by David Genecov and John Harkey.